WallStSmart

20/20 Biolabs, Inc. Common Stock (AIDX)vsGE HealthCare Technologies Inc. (GEHC)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 1060433% more annual revenue ($21.64B vs $2.04M). GEHC leads profitability with a 9.9% profit margin vs -285.0%. GEHC earns a higher WallStSmart Score of 66/100 (B-).

AIDX

Hold

36

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 6.0
Piotroski: 4/9Altman Z: -13.90

GEHC

Strong Buy

66

out of 100

Grade: B-

Growth: 6.7Profit: 7.0Value: 5.7Quality: 4.5
Piotroski: 2/9Altman Z: 1.34

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AIDX3 strengths · Avg: 9.0/10
Revenue GrowthGrowth
36.5%10/10

Revenue surging 36.5% year-over-year

Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

GEHC2 strengths · Avg: 8.0/10
P/E RatioValuation
17.7x8/10

Attractively priced relative to earnings

EPS GrowthGrowth
39.0%8/10

Earnings expanding 39.0% YoY

Areas to Watch

AIDX4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.62M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-354.6%2/10

ROE of -354.6% — below average capital efficiency

Free Cash FlowQuality
$-610,8142/10

Negative free cash flow — burning cash

GEHC3 concerns · Avg: 3.0/10
PEG RatioValuation
2.254/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AIDX

The strongest argument for AIDX centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 36.5% demonstrates continued momentum.

Bull Case : GEHC

The strongest argument for GEHC centers on P/E Ratio, EPS Growth.

Bear Case : AIDX

The primary concerns for AIDX are EPS Growth, Market Cap, Return on Equity.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, Altman Z-Score.

Key Dynamics to Monitor

AIDX profiles as a hypergrowth stock while GEHC is a value play — different risk/reward profiles.

GEHC carries more volatility with a beta of 0.77 — expect wider price swings.

AIDX is growing revenue faster at 36.5% — sustainability is the question.

GEHC generates stronger free cash flow (793M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (66/100 vs 36/100). Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

20/20 Biolabs, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

20/20 Biolabs, Inc. (AIDX) is a pioneering biotechnology company dedicated to advancing genomic research and diagnostics through its cutting-edge laboratory services. Focused on improving the accuracy and efficiency of genetic testing for both clinical and research applications, the company is set to establish itself as a leader in the molecular diagnostics market. With a strategic emphasis on personalized medicine and a robust portfolio of state-of-the-art technologies, 20/20 Biolabs is well-positioned to meet the surging demand for genomic data and capitalize on emerging opportunities within the dynamic biotechnology landscape. Its innovative approach and strong market presence reflect a promising growth trajectory in an industry characterized by rapid advancements.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?